Ambit and Astellas Sign $350M Development Deal
The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer called acute relapsed/refractory myeloid leukemia (AML).
Possible Cause of Inflammatory Bowel Disease Uncovered
A researcher at the University of Adelaide found that people suffering from inflammatory bowel disease have a lower number of regulatory cells that control the immune system.
Cubist/Calixa Deal the Latest in a String of Biotech Buyouts
Cubist Pharmaceuticals has announced plans to acquire tiny San Diego biotech Calixa Therapeutics for up to $402.5 million.
[Company Profile] MicroPhage
MicroPhage of Longmont, Colo., has developed a platform of rapid diagnostic tests to identify staph bacteria and determine methicillin resistance (MRSA) and susceptibility (MSSA).
ThromboGenics Starts Phase II Trial for Macular Degeneration Therapy
ThromboGenics, a company specializing in biotherapeutics for vascular diseases, cancer, and eye diseases, has announced the start of a Phase II trial of microplasmin to treat age-related wet macular degeneration (AMD).
Cytori’s (NASDAQ: CYTX) Natural Celution for Breast Reconstruction
Cytori Therapeutics is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types.
[Company Profile] Stentys
Medical device company Stentys seeks to correct the problem of poor apposition with its self-expanding stent technology.
Bioguard Wound Dressings Beat Swine Flu In Independent Study
Derma Sciences, a developer of wound care products, announced that its Bioguard Barrier Dressings effectively safeguarded against the H1N1 “swine flu” virus in an independent laboratory study.
Celgene Acquires Gloucester In $340M Deal
Biopharmaceutical company Celgene is plumping up its oncology pipeline with its latest acquisition.
Vertex to Sell 1.5 Million Shares
Vertex Pharmaceuticals has been busy raising cash to prepare for the launch of telaprevir to treat hepatitis C.